Given that a higher prognostic value of the 53BP1 status in tumor tissue had been reported for TNBC patients [26], we compared CTCs from HR-, i.e., TNBC, and HR+ MBC patients who otherwise featured comparable clinical characteristics (Table 1). This evidence concerns the gene TP53BP1 and neoplasm.